BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 07, 2008
 |  BioCentury  |  Product Development

Cleaner than triptans

Triptans are the drug of choice for migraine patients, but they have cardiovascular side effects that leave many healthy patients wary and make them contraindicated for patients with CV disease. Merck & Co. Inc. disclosed Phase III data recently for a new compound class that looks to have similar efficacy without the cardiovascular risk.

At the American Headache Society meeting in Boston, Merck presented data from a double-blind, placebo- and active-controlled trial of MK-0974 telcagepant vs. Zomig zolmitriptan from AstraZeneca plc showing that 55% of patients in the 300 mg MK-0974 arm had headache relief within two hours vs. 56% for 5 mg Zomig and 28% for placebo.

MK-0974 also had comparable efficacy to Zomig on measures of experiencing some form of head relief at two hours (27% telcagepant, 31% Zomig), absence of phonophobia (58%, 55%), absence of photophobia (51%, 50%) and absence of nausea (65%, 71%).

However, telcagepant patients reported a lower overall...

Read the full 766 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >